A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis

K. Papp; D. Pariser; M. Catlin; G. Wierz; G. Ball; B. Akinlade; B. Zeiher; J.G. Krueger

doi:10.1111/bjd.13745

A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis

British Journal of Dermatology ◽

10.1111/bjd.13745 ◽

2015 ◽

Vol 173 (3) ◽

pp. 767-776 ◽

Cited By ~ 53

Author(s):

K. Papp ◽

D. Pariser ◽

M. Catlin ◽

G. Wierz ◽

G. Ball ◽

...

Keyword(s):

Dose Escalation ◽

Kinase Inhibitor ◽

Severe Psoriasis ◽

Janus Kinase ◽

Efficacy And Safety ◽

Dose Escalation Study ◽

Double Blind ◽

Janus Kinase Inhibitor ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725364136.793541451 ◽

2018 ◽

Author(s):

William Vainchenker ◽

Isabelle Plo

Keyword(s):

Dose Escalation ◽

Kinase Inhibitor ◽

Severe Psoriasis ◽

Janus Kinase ◽

Efficacy And Safety ◽

Dose Escalation Study ◽

Double Blind ◽

Janus Kinase Inhibitor ◽

Double Blind Placebo

Download Full-text

OP0202 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: opal beyond, a randomised, double-blind, placebo-controlled, phase 3 trial

10.1136/annrheumdis-2017-eular.2443 ◽

2017 ◽

Cited By ~ 3

Author(s):

DD Gladman ◽

WFC Rigby ◽

VF Azevedo ◽

F Behrens ◽

R Blanco ◽

...

Keyword(s):

Tumour Necrosis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Inadequate Response ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Janus Kinase Inhibitor ◽

Double Blind Placebo ◽

Necrosis Factor

Download Full-text

Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.12081 ◽

2013 ◽

Vol 28 (2) ◽

pp. 192-203 ◽

Cited By ~ 38

Author(s):

C. Mamolo ◽

J. Harness ◽

H. Tan ◽

A. Menter

Keyword(s):

Patient Reported Outcomes ◽

Kinase Inhibitor ◽

Severe Psoriasis ◽

Janus Kinase ◽

Controlled Study ◽

Double Blind ◽

Janus Kinase Inhibitor ◽

Double Blind Placebo ◽

Patient Reported

Download Full-text

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumor necrosis factor inhibitors: OPAL Beyond, a randomized, double blind, placebo-controlled, phase 3 trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2017.04.451 ◽

2017 ◽

Vol 76 (6) ◽

pp. AB114

Keyword(s):

Tumor Necrosis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Inadequate Response ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Janus Kinase Inhibitor ◽

Double Blind Placebo ◽

Necrosis Factor

Download Full-text

Efficacy and safety of topical delgocitinib (JTE-052), janus kinase inhibitor, in Japanese pediatric patients with atopic dermatitis: A phase II, randomized, double-blind, vehicle-controlled study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.06.224 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB53

Keyword(s):

Atopic Dermatitis ◽

Phase Ii ◽

Pediatric Patients ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Janus Kinase Inhibitor

Download Full-text

A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis

Journal of Dermatological Treatment ◽

10.3109/09546634.2015.1115819 ◽

2016 ◽

Vol 27 (4) ◽

pp. 332-338 ◽

Cited By ~ 32

Author(s):

Robert Bissonnette ◽

Monica Luchi ◽

Rosanne Fidelus-Gort ◽

Shawnta Jackson ◽

Haifeng Zhang ◽

...

Keyword(s):

Dose Escalation ◽

Plaque Psoriasis ◽

Janus Kinase ◽

Chronic Plaque Psoriasis ◽

Dose Escalation Study ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Janus Kinase 1

Download Full-text

Efficacy and safety of topical delgocitinib (JTE-052), janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: A phase III, randomized, double-blind, vehicle-controlled study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.06.737 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB199

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Phase Iii ◽

Controlled Study ◽

Severe Atopic Dermatitis ◽

Efficacy And Safety ◽

Japanese Adult ◽

Double Blind ◽

Janus Kinase Inhibitor

Download Full-text

Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study

British Journal of Dermatology ◽

10.1111/bjd.16004 ◽

2018 ◽

Vol 179 (1) ◽

pp. 54-62 ◽

Cited By ~ 27

Author(s):

G.J. Schmieder ◽

Z.D. Draelos ◽

D.M. Pariser ◽

C. Banfield ◽

L. Cox ◽

...

Keyword(s):

Phase Ii ◽

Severe Psoriasis ◽

Janus Kinase ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Janus Kinase 1

Download Full-text

Faculty Opinions recommendation of A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13409136.14780164 ◽

2011 ◽

Author(s):

John Laffey ◽

Mairead Hayes

Keyword(s):

Myocardial Infarction ◽

Acute Myocardial Infarction ◽

Stem Cells ◽

Mesenchymal Stem Cells ◽

Dose Escalation ◽

Human Mesenchymal Stem Cells ◽

Dose Escalation Study ◽

Double Blind ◽

Double Blind Placebo ◽

Adult Human

Download Full-text

Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies

Reumatología Clínica (English Edition) ◽

10.1016/j.reumae.2017.04.009 ◽

2019 ◽

Vol 15 (1) ◽

pp. 43-53

Author(s):

Ruben Burgos-Vargas ◽

Mario Cardiel ◽

Daniel Xibillèc) ◽

Cèc)sar Pacheco-Tena ◽

Virginia Pascual-Ramos ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Efficacy And Safety ◽

Phase 3 ◽

Janus Kinase Inhibitor

Download Full-text